Cargando…

The SARS-CoV-2 responsible for phlegmasia cerulea dolens: a case report

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic systemic infection that is responsible for serious coagulopathies similar to disseminated intravascular coagulation. CASE PRESENTATION: The authors report the case of a COVID-19 patient who presented with phlegmasia cerulea dolens (PCD) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Banana, Youssef, Bashir, Husam, Boukabous, Sara, Haddiya, Intissar, Bentata, Yassamine, Rezziki, Abdellah, Benzirar, Adnane, El Mahi, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060091/
https://www.ncbi.nlm.nih.gov/pubmed/37008170
http://dx.doi.org/10.1097/MS9.0000000000000152
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) is a worldwide pandemic systemic infection that is responsible for serious coagulopathies similar to disseminated intravascular coagulation. CASE PRESENTATION: The authors report the case of a COVID-19 patient who presented with phlegmasia cerulea dolens (PCD) of the left lower limb, so he benefited from aponeurotomies of the internal and anterolateral muscular compartments. CLINICAL DISCUSSION: The severe acute respiratory syndrome coronavirus 2 involves an inflammatory process in thrombotic events in COVID-19 patients, including a cytokine storm. PCD evolves in three semiological phases: venous stasis, weakening of the pulses, and the constitution of major ischemia. In the literature, the authors find many reports that have been published regarding increased thrombus formation in COVID-19 patients; these include DVT formation, pulmonary embolism, and stroke. Nevertheless, publications concerning PCD in COVID-19 patients remain rare. CONCLUSION: Although the severe acute respiratory syndrome coronavirus 2 remains a thrombogenic pathology, systematic anticoagulation is the subject of hypothesis. Hence the importance of regular monitoring of markers of vascular thrombosis.